BHVN:NYSE, Biohaven Ltd.
BHVN stock overview
Biohaven Ltd. (BHVN:NYSE) closed at $13.88 on October 23, 2026,
down 5.51% on the day.
The stock trades 25.2% below its 52-week high of $18.57
and 85.6% above its 52-week low of $7.48.
Over the past year, it lost 16.4%.
Biohaven Ltd. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $13.88
- Day change
- -5.51%
- Volume
- 4,690,019
- Average volume
- 3,051,001
- Market cap
- 2B+
- 52-week range
- $7.48 – $18.57
- 50-day average
- $13.51
- 200-day average
- $12.11
Price action over the past year
In 252 trading sessions since October 23, 2025, BHVN closed higher on 112 days (44%).
Its best day was October 22, 2026 (+25.02%) and its worst was November 5, 2025 (-40.22%).
The stock moved 10% or more in a single session 17 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
BHVN news
-
Oct 23, 2026:
Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says
-
Oct 23, 2026:
Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance
-
Oct 23, 2026:
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade
-
Oct 22, 2026:
Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting
-
Oct 22, 2026:
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again
-
Oct 22, 2026:
Biohavens previously rejected rare disease drug to get fresh FDA review
-
Oct 22, 2026:
Biohaven's previously rejected rare disease drug to get fresh FDA review
-
Oct 22, 2026:
Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting
About Biohaven Ltd.
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
Similar stocks
Find more stocks like BHVN with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.